Skip to main content
Przejdź do strony domowej Komisji Europejskiej (odnośnik otworzy się w nowym oknie)
polski pl
CORDIS - Wyniki badań wspieranych przez UE
CORDIS

personalised Diabetes Management using lOw-cost Needle-free multiple-biomarkers monitoring Device

Cel

"""Diabetes is the #1 health challenge of the 21st century. Continuous Glucose Monitoring or CGM ($1.25B market in 2016, growing 29%/yr) is today’s cornerstone of “diabetes self-management” and the most effective solution to reduce the economic and societal burden of diabetes. But the shortcomings of current CGMs hinder their wider adoption: high cost, unsatisfactory predictability of severe events, and poor user comfort. The DiaMOND project will remove these barriers by bringing needle-free, low-cost Continuous Diabetes Monitoring to market. DiaMOND is specifically geared at extending Indigo’s current CGM with reliable severe clinical event prediction and a great user experience; demonstrating the reliability in a first-in-man trial; creating market acceptance by involving Key Opinion Leaders; and obtaining reimbursement. Indigo will be ready for a large pivotal clinical study and CE marking after completing the DiaMOND project. DiaMOND will accelerate Indigo’s CDM market access by 2-3 years."""

Dziedzina nauki (EuroSciVoc)

Program(-y)

Temat(-y)

System finansowania

SME-2 - SME instrument phase 2

Wyświetl wszystkie projekty finansowane w ramach tego programu finansowania

Zaproszenie do składania wniosków

(odnośnik otworzy się w nowym oknie) H2020-EIC-SMEInst-2018-2020

Wyświetl wszystkie projekty finansowane w ramach tego zaproszenia

Koordynator

INDIGO DIABETES
Wkład UE netto
€ 2 493 273,13
Adres
BOLLEBERGEN 2B/30
9052 Gent
Belgia
MŚP
Tak
Region
Vlaams Gewest Prov. Oost-Vlaanderen Arr. Gent
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Linki
Koszt całkowity
€ 4 519 408,75